Crossmark

Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion

Crossref DOI link: https://doi.org/10.1186/s12885-019-5527-2

Published Online: 2019-04-03

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Furugaki, Koh

Mochizuki, Marie

Kohno, Mirei

Shu, Sei

Harada, Naoki

Yoshimura, Yasushi
Funding

Funding for this research was provided by:

Chugai Pharmaceutical
License Information

Text and Data Mining valid from 2019-04-03
More Information

Article History

Received: 10 May 2018

Accepted: 27 March 2019

First Online: 3 April 2019

Ethics approval and consent to participate

: Not applicable because all materials were commercially available products. All studies were ethically reviewed and approved by the ethical review committee at Chugai Pharmaceutical Co., Ltd..

: Not applicable.

: The authors are employees of Chugai Pharmaceutical Co., Ltd., and declare no conflict of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.